PCM
ORIC icon

Penserra Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Penserra Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-900
Closed -$18K – 1492
2021
Q3 		$18K Buy
900
+65
+8% +$1.32K ﹤0.01% 1264
2021
Q2 		$14K Buy
835
+10
+1% +$219 ﹤0.01% 1241
2021
Q1 		$20K Sell
825
-15
-2% -$474 ﹤0.01% 968
2020
Q4 		$28K Buy
+840
New +$24.1K ﹤0.01% 800

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Penserra Capital Management's ORIC Position: Q4 2021 in Review

Penserra Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q4 2021, closing a stake of 900 shares — an estimated $18K sold.

Penserra Capital Management first reported a position in ORIC in Q4 2020 and held it in 4 quarters. The position peaked at $28K in Q4 2020. 80 funds tracked by Wall St. Rank hold ORIC as of Q4 2021.

  • Penserra Capital Management reported no remaining Oric Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 900 Oric Pharmaceuticals shares in Q4 2021, an estimated $18K.
  • Penserra Capital Management first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Oric Pharmaceuticals position peaked at $28K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.